Celcuity Inc

CELCStocksMedical SpecialtiesUnited StatesNasdaqUSD

Price

$71.52

Today

-0.8%

YTD

-27.6%

About

Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for cancer. The company's lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor. Celcuity is conducting a Phase 3 registration-enabling clinical trial to evaluate gedatolisib in patients with HR+/HER2- advanced breast cancer. Celcuity operates in the biotechnology sector. Its products are targeted therapies that are designed to disrupt cancer cell signalling pathways and inhibit tumour growth. Celcuity is not part of a larger organisation and does not have any subsidiaries. Explore CELC share prices and other stocks on eToro.

Price chart

Closing price history for CELC (1D candles).

Open positions

Current open positions for this instrument from your live portfolio.

Open positions

Unrealized return

+0.0%

No open positions exist for this instrument at the moment.

Financial insights

Valuation

P/E (TTM)-16.77

P/S (TTM)0.00

P/B (TTM)-275.98

Market cap$3.53B

Cap tierMid-cap

Industry avg P/E17.08

Profitability

Gross marginUnknown

EBIT margin0.00%

Net marginUnknown

ROE-1433.70%

ROA-44.77%

Earnings & Revenue

Revenue (TTM)$0.00

Revenue growth (1Y)Unknown

EPS (TTM)-$4.30

Free cash flow$-192.12M

Total debt$754.38M

Dividends & Risk

Dividend rate$0.00

Dividend yield0.00%

Beta (5Y)1.15

Employees155

Next earnings11 Nov '26

Trade history

Closed trades

Realized return

+0.0%

No stored closed trades exist for this instrument yet.